With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). The nonsteroidal mineralocorticoid receptor antagonist (MRA) was approved ...

Bayer announces primary endpoint achieved in phase III FINEARTS-HF cardiovascular outcomes study investigating Kerendia (finerenone) in patients with heart failure with mildly reduced or preserved ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...

FINEARTS-HF is one of four phase 3 studies that Bayer is hoping to make finerenone a go-to therapy for heart failure patients, alongside the REDEFINE-HF trial of the drug as monotherapy in ...

Finerenone also reduced urine albumin-creatinine ... FINEARTS-HF was funded by Bayer. Some co-authors are company employees. McCausland disclosed relationships with the National Institute of ...

For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone, ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary albumin-to-creatinine ratio (UACR) in patients with albuminuria and both chronic kidney ...

In order for the drug to get FDA approval for use in these people with heart failure, Bayer, the pharmaceutical company behind finerenone, would need to apply to the agency for an expanded indication.

After final results were announced 1 on September 1 at the European Society of Cardiology (ESC) Congress in London, there is strong reason to believe finerenone (Kerendia; Bayer) will have real ...

and type 2 diabetes to finerenone (Kerendia, Bayer) 10 mg or 20 mg per day plus placebo (n = 264), empagliflozin (Jardiance, Boehringer Ingelheim) 10 mg per day plus placebo (n = 267) or ...

In that announcement, Dr. Christian Rommel, head of research and development at Bayer’s Pharmaceuticals Division, said the company is “eager to bring finerenone to eligible patients as soon as ...

In that announcement, Dr. Christian Rommel, head of research and development at Bayer’s Pharmaceuticals Division, said the company is “eager to bring finerenone to eligible patients as soon as ...